sgmo stock price touched intra-day lows at $0.52 yesterday after reports of competitive therapies entering late-stage trials. This raised concerns about market share retention for Sangamo's lead candidates. While the broader market gained around 16% in the last year, Sangamo Therapeutics shareholders lost 17%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. However, the loss over the last year isn't as bad as the 14% per annum loss investors have suffered over the last half decade. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. It's always interesting to track share price performance over the longer term. But to understand Sangamo Therapeutics better, we need to consider many other factors. Take risks, for example - Sangamo Therapeutics has 4 warning signs (and 1 which doesn't sit too well with us) we think you should know about. Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. SGMO's latest investor presentation notes several regulatory submissions planned for H